| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-059 | | --- | --- | --- | | 转债代码：118010 | 转债减持：洁特转债 | | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由董事会召集，会议采取现场投票和网络投票相结合的表决方式。 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 16 日 （二） 股东大会召开的地点：广东省广州市黄埔区经济技术开发区永和经济区 斗塘路 1 号公司 A1 栋五楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 44 | | --- | --- | | 普通股股东人数 | 44 | | 2、出席会议的股东所持有的表决权数量 | 64,667,085 | | 普通股股东所持有表决权数量 | 64,667,085 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 46.0708 | | 例（%） | | | 普通股股东所持有 ...

Investment Rating - The report maintains a "Buy" rating for the company [9] Core Viewpoints - The company's performance met expectations with significant market expansion, achieving revenue of 268 million yuan in the first half of 2025, a year-on-year increase of 13.50% [6][12] - The company actively expanded its customer base, adding 623 new clients in the first half of 2025, and developed 56 new product specifications across 13 series based on customer needs [2][12] - Gross margin improved to 42.57%, up 1.16 percentage points from 41.41% in 2024, while net margin increased to 17.74%, up 4.68 percentage points from 13.06% in 2024, driven by enhanced production efficiency and scale effects [12] - The company focused on overseas markets, generating 168 million yuan in overseas revenue, accounting for approximately 62.83% of total revenue, with over 30% from the U.S. market [12] - The company has developed a comprehensive product system with over 100 specifications across seven major categories in laboratory consumables and a series of biological reagents [12] - Future profit projections for the company are optimistic, with expected net profits of 90 million, 113 million, and 143 million yuan for 2025, 2026, and 2027 respectively, corresponding to PE ratios of 30, 24, and 19 times [12]

Core Viewpoint - Jiet Bio announced the resignation of its securities affairs representative, Ms. Xing Wanfang, due to personal reasons, effective immediately upon delivery of the resignation report to the board [1] Company Summary - Ms. Xing Wanfang will no longer hold any position within the company following her resignation [1] - The responsibilities handled by Ms. Xing have been successfully transitioned, ensuring that the company's operations will continue without disruption [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-057 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于证券事务代表辞职的公告 特此公告。 广州洁特生物过滤股份有限公司董事会 2025 年 9 月 13 日 1 广州洁特生物过滤股份有限公司（以下简称"公司"）董事会于近日收到证 券事务代表邢婉芳女士的书面辞职报告。邢婉芳女士因个人原因申请辞去公司证 券事务代表一职，辞职后将不再担任公司任何职务，辞职报告自送达董事会之日 起生效，其负责的工作已完成交接，其辞职不会影响公司相关工作的正常开展。 邢婉芳女士在担任公司证券事务代表期间，恪尽职守、勤勉尽责，在公司治 理、信息披露及规范运作等方面发挥了积极的作用，公司及董事会对邢婉芳女士 在职期间为公司发展做出的努力和贡献表示衷心感谢！ 公司董事会将根据《上海证券交易所科创板股票上市规则》等相关规定，尽 快聘任符合任职资 ...

Core Points - The company announced that its board of directors received a written resignation letter from Ms. Xing Wanfang, the securities affairs representative [1] - Ms. Xing resigned due to personal reasons and will no longer hold any position within the company after her resignation [1] - The work she was responsible for has been successfully handed over, and her resignation will not affect the normal operations of the company's related work [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、对外投资设立产业基金概述 广州洁特生物过滤股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日召 开第四届董事会第二十一次会议，审议通过了《关于拟对外投资设立产业基金的 议案》。为深化落实公司战略发展规划，加深产业资本合作，借助专业投资机构 的力量及资源优势通过股权投资进一步发掘具有产业协同效应的优质项目，助力 公司长远发展，公司与广州南粤澳洋基金管理有限公司（以下简称"南粤澳洋"）、 广州南粤基金集团有限公司（以下简称"南粤基金"）出资发起设立广州增城区 南特生物医药投资合伙企业（有限合伙）（以下简称"南特投资"），主要投资 于早、中期生物医药类项目，产业基金总出资额为人民币 5,001 万元，其中公司 作为有限合伙人认缴出资人民币 2,500 万元，占认缴出资额的 49.99%。 具体内容详见公司于 2025 年 7 月 4 日披露的《关于拟对外投资设立产业基 金的公告》（公告编号：2025-042）。 二、对外投资设立产业基金的进展情况 | 证券代码：6 ...

广州洁特生物过滤股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688026 证券简称：洁特生物 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 9 月 16 日 1 广州洁特生物过滤股份有限公司 2025 年第二次临时股东大会会议资料 股东大会须知 为保障广州洁特生物过滤股份有限公司全体股东的合法权益，维护股东大会 的正常秩序，保证股东大会的议事效率，确保本次股东大会如期、顺利召开，根 据《公司法》《公司章程》《股东大会议事规则》及中国证监会、上交所的有关规 定，特制定本须知。 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东（或股东代表） 的合法权益，除出席会议的股东（或股东代表）、公司董事、监事、高级管理人员、 见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入会场。 三、出席会议的股东（或股东代表）须在会议召开前 30 分钟到会议现场办理 签到手续，并请按规定出示证券账户卡、身份证或法人单位证明、授权委托书等， 经验证后方可 ...

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

Market Performance - The medical device sector increased by 1.87% on September 1, with Yirui Biological leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Device Sector - Yirui Biological (300942) closed at 13.82, up 13.56% with a trading volume of 263,400 shares and a transaction value of 350 million [1] - Jimin Health (603222) closed at 12.67, up 9.98% with a trading volume of 1,050,500 shares [1] - Hualan Biological (301093) closed at 37.16, up 9.55% with a trading volume of 123,900 shares [1] - Huatai Medical (688617) closed at 305.49, up 7.43% with a trading volume of 30,100 shares [1] - United Imaging Healthcare (688271) closed at 152.10, up 7.26% with a trading volume of 147,200 shares [1] Top Losers in Medical Device Sector - Toukeng Life (300642) closed at 28.50, down 7.71% with a trading volume of 234,300 shares [2] - Blue Sail Medical (002382) closed at 5.99, down 3.07% with a trading volume of 288,400 shares [2] - Wuzhou Medical (301234) closed at 43.30, down 2.48% with a trading volume of 20,800 shares [2] Capital Flow Analysis - The medical device sector saw a net inflow of 68.08 million from institutional investors, while retail investors contributed a net inflow of 14.9 million [2] - The sector experienced a net outflow of 217 million from speculative funds [2] Individual Stock Capital Flow - Mindray Medical (300760) had a net inflow of 90.24 million from institutional investors, while it faced a net outflow of 128 million from speculative funds [3] - United Imaging Healthcare (688271) saw a net inflow of 87.93 million from institutional investors, with a net outflow of 130 million from speculative funds [3] - Jimin Health (603222) experienced a net inflow of 79.82 million from institutional investors, but a net outflow of 49.23 million from speculative funds [3]

2025年8月30日，洁特生物(688026.SH)发布2025年中报。 公司营业总收入为2.68亿元，较去年同报告期营业总收入增加3189.25万元，实现2年连续上涨，同比较 去年同期上涨13.50%。归母净利润为4633.86万元，较去年同报告期归母净利润增加1633.84万元，实现 2年连续上涨，同比较去年同期上涨54.46%。经营活动现金净流入为8416.94万元，在已披露的同业公司 中排名第44，较去年同报告期经营活动现金净流入增加6870.25万元，同比较去年同期上涨444.19%。 | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 袁建华 | 29.26% | | 2 | JET(H.K.) BIOSCIENCE CO., LIMITED | 12.50% | | 3 | 洛阳麦金顿企业管理合伙企业(有限合伙) | 1.70% | | 4 | 珠海阿巴马私募基金投资管理有限公司-阿巴马元享红利80号私募证券投资基金 | 1.42% | | 5 | 中国银行股份有限公司-嘉实领先优势混合型证券投资基金 | 1.19% | | ଚ | 广州萝岗区汇资投资管 ...